3,4-二氢-2H-苯并吡喃-3-甲醇 | 76727-28-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 中文名称: 3,4-二氢-2H-苯并吡喃-3-甲醇
• 英文名称: 3-hydroxymethylchromane
• 英文别名: chroman-3-ylmethanol；3,4-dihydro-2H-chromen-3-ylmethanol
• CAS: 76727-28-1
• 化学式: C₁₀H₁₂O₂
• 分子量: 164.204
• InChiKey: UPDSWAQIQZFOLF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险类别码：
  R36/37/38
• 海关编码：
  2932999099
• 安全说明：
  S24/25

SDS

Name:	3 4-Dihydro-2h-chromen-3-ylmethanol 97% Material Safety Data Sheet
Synonym:
CAS:	76727-28-1

Section 1 - Chemical Product MSDS Name:3 4-Dihydro-2h-chromen-3-ylmethanol 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
76727-28-1	3,4-Dihydro-2H-chromen-3-ylmethanol	97%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 76727-28-1: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 61.5 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C10H12O2
Molecular Weight: 164.2

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 76727-28-1 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
3,4-Dihydro-2H-chromen-3-ylmethanol - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 76727-28-1: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 76727-28-1 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 76727-28-1 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3,4-二氢-2H-苯并吡喃-3-甲醇 在 bis(1,5-cyclooctadiene)diiridium(I) dichloride 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 、 lithium chloride 作用下， 以 水 、 均三甲苯 为溶剂， 反应 16.0h， 以87%的产率得到3,4-二氢-1H-苯并吡喃
  参考文献：
  名称：

  Iridium catalysis: reductive conversion of glucan to xylan

  摘要：

  铱催化的脱氢脱羰基反应被用于将纤维二糖转化为木聚糖，用于快速组装寡木聚糖。

  DOI：

  10.1039/c7cc09260a
• 作为产物：
  描述：

  2H-苯并吡喃-3-甲酸 在 palladium on activated charcoal lithium aluminium tetrahydride 、 氢气 作用下， 以 乙醚 、 乙醇 为溶剂， 反应 6.0h， 生成 3,4-二氢-2H-苯并吡喃-3-甲醇
  参考文献：
  名称：

  Pharmacomodulation d'adrénolytiques aα en série benzopyrannique

  摘要：

  DOI：

  10.1016/0223-5234(87)90294-7

文献信息

• [EN] TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE<br/>[FR] INHIBITEURS DE MYÉLOPEROXYDASE DE TYPE TRIAZOLOPYRIDINE ET TRIAZOLOPYRIMIDINE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2016040417A1

  公开（公告）日：2016-03-17

  The present invention provides compounds of Formula (I): wherein A and R1 are each as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, which may be used as medicaments.

  本发明提供了式（I）的化合物：其中A和R1如规范中所定义，并包括任何此类新化合物的组合物。这些化合物是髓过氧化物酶（MPO）抑制剂和/或嗜酸性粒细胞过氧化物酶（EPX）抑制剂，可用作药物。
• Light‐Promoted Nickel Catalysis: Etherification of Aryl Electrophiles with Alcohols Catalyzed by a Ni ^II ‐Aryl Complex
  作者：Liu Yang、Huan‐Huan Lu、Chu‐Hui Lai、Gang Li、Wei Zhang、Rui Cao、Fengyi Liu、Chao Wang、Jianliang Xiao、Dong Xue

  DOI：10.1002/anie.202003359

  日期：2020.7.27

  highly effective C−O coupling reaction of (hetero)aryl electrophiles with primary and secondary alcohols is reported. Catalyzed by a NiII‐aryl complex under long‐wave UV (390–395 nm) irradiation in the presence of a soluble amine base without any additional photosensitizer, the reaction enables the etherification of aryl bromides and aryl chlorides as well as sulfonates with a wide range of primary

  据报道，（杂）芳基亲电试剂与伯醇和仲醇的高效C-O偶联反应。在可溶性胺碱的存在下，在没有任何其他光敏剂的情况下，在长波紫外线（390–395 nm）辐射下，由Ni II-芳基络合物催化，该反应可以使芳基溴化物和芳基氯化物以及磺酸盐与多种伯和仲脂族醇，可提供合成上重要的醚。分子内CO偶联也是可能的。该反应似乎通过Ni I -Ni III催化循环进行。
• Synthesis and Structure-Activity Relationships of Triazaspirodecanone Derivatives as Nociceptin/Orphanin FQ Receptor Ligands
  作者：Sandra Corrado、Umberto M. Battisti、Claudia Sorbi、Annalisa Tait、Davide Malfacini、Valeria Camarda、Girolamo Calò、Livio Brasili

  DOI：10.1111/cbdd.12505

  日期：2015.10

  to the CH2 linked to the 1‐phenyl‐1,3,8‐triaza‐spiro[4.5]decan‐4‐one portion. Moreover, cis diastereoisomers of the hydroxyl derivatives4 and 22 show a moderately higher degree of stereoselectivity than trans isomers. In particular, the spiropiperidine derivative cis‐4 has submicromolar agonistic activity, and it will be the reference compound for the design and synthesis of new NOP agonists.

  合成了几种螺索托林衍生物，并将其评估为潜在的NOP受体配体。螺氧杂环丁烷的1,4-苯并二恶烷部分的结构修饰一直是该研究项目的重点。出现的结构-活性关系表明，当H-键供体基团（羟基）相对于与1-苯基-1,3连接的CH 2处于α位置时，它更有利于NOP活性， 8-triaza-spiro [4.5] decan-4-一份。此外，羟基衍生物4和22的顺式非对映异构体显示出比反式异构体适度更高的立体选择性。尤其是螺哌啶衍生物cis - 4具有亚微摩尔激动活性，它将成为设计和合成新的NOP激动剂的参考化合物。
• Synthesis of Robalzotan, Ebalzotan, and Rotigotine Precursors via the Stereoselective Multienzymatic Cascade Reduction of α,β-Unsaturated Aldehydes
  作者：Elisabetta Brenna、Francesco G. Gatti、Luciana Malpezzi、Daniela Monti、Fabio Parmeggiani、Alessandro Sacchetti

  DOI：10.1021/jo4003097

  日期：2013.5.17

  The key step is based on a multienzymatic reduction of an α,β-unsaturated aldehyde or ketone to give the saturated primary or secondary alcohol, in a high yield and with a high ee. The catalytic system consists of the combination of an ene-reductase (ER; i.e., OYE2 or OYE3 belonging to the Old Yellow Enzyme family) with an alcohol dehydrogenase (ADH), applying the in situ substrate feeding product removal

  据报道，基于四氢化萘或苯并二氢吡喃结构部分的立体选择性合成双环伯胺或仲胺。这些胺是重要的活性药物成分（如罗替戈汀（Neupro），罗巴唑坦和依巴唑坦）的前体。关键步骤是基于α，β-不饱和醛或酮的多酶还原，以高收率和高ee值得到饱和伯醇或仲醇。催化系统由烯还原酶（ER；即属于Old Yellow Enzyme家族的OYE2或OYE3）与醇脱氢酶（ADH）结合而成，采用原位底物进料产品去除技术。通过该系统，烯丙基醇副产物的形成和手性不稳定的α-取代的醛中间体的外消旋化被最小化。通过库尔修斯重排精制伯醇。OYE2与Prelog或抗Prelog ADH的组合可以制备ee> 99％和de> 87％的仲醇。通过与真实样品进行比较，明确确定了伯胺的绝对构型。通过X射线晶体结构和Mosher酯的NMR分析确定仲醇的立体化学。
• Compounds that modulate PPAR activity and methods of preparation
  申请人：——

  公开号：US20030207915A1

  公开（公告）日：2003-11-06

  This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing hyperlipidemia and hypercholesteremia in a mammal. The present invention also discloses method for making the disclosed compounds.

  这项发明揭示了能够改变PPAR活性的化合物。该发明还揭示了这些化合物的药用盐、包含这些化合物或其盐的药用组合物，以及将它们用作治疗或预防哺乳动物高脂血症和高胆固醇血症的治疗剂的方法。本发明还揭示了制备所述化合物的方法。